# A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HSY244 in Participants With Atrial Fibrillation

> **NCT04582409** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 13 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** HSY244
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04582409
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-11-30
- **Primary completion:** 2022-07-11
- **Final completion:** 2022-07-11
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Terminated due to business decision
- **Last updated:** 2024-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04582409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04582409, "A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HSY244 in Participants With Atrial Fibrillation". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04582409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*